Tavec Completes $850,000 Seed Funding

Proceeds to further pre-clinical development of exosome mediated gene therapy technology platform for cancer

NEW YORK, June 15th, 2015 – Tavec, Inc. (Tavec) announced today that it has secured $850,000 in seed funding to complete key pre-clinical validation studies and further development of intellectual property.

Tavec’s exosome mediated technology enables the delivery by injection of anti-cancer molecules, including regulatory RNA, directly to cancer cells to disrupt growth and metastasis. Exosomes are small, naturally occurring vesicles which can be grown to enable highly-specific targeting of cancer cells.

Tavec completed an exclusive, worldwide license from The Johns Hopkins University on its seminal technology in June of 2015.


About Tavec’s Exosome RNA Therapy

At Tavec, we load key regulatory molecules, called micro-ribonucleic acids or “miRNA” into the body’s natural exosome delivery system to create powerful anti-cancer therapeutics. Our exosomes are prepared to specifically target cancer cells and deliver their genetic payloads to effect maximum disruption on cancer growth. miRNAs are powerful “non-coding” molecules that have the ability to shut-down or disrupt the key genetic messages responsible for cancer growth and metastasis.  Exosomes are small, naturally formed vesicles secreted by all human cell types into circulation. Because they are normally produced by the body, exosomes are non-immunogenic, meaning they do not cause an immune response or “rejection” and act as ideal circulating delivery vehicles.  Exosomes have a lipid coating that protects their cargo from RNA-degrading enzymes in blood and other body fluids.  We produce specialized types of exosomes that are selectively taken up by cancer cells and can be used to deliver tumor suppressive miRNAs and other disruptive molecules to cancer cells with minimal effects on normal tissue.